HENRY FORD HEALTH SYSTEM

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1915-01-01

Employees: 5K

Market Cap: -

Website: http://www.henryford.com

Clinical Trials

Negative Pressure Wound Therapy for Surgical Site Infection Prevention in Common Femoral Artery Exposure

Not Applicable

Withdrawn

Conditions: Groin Infections
Surgical Site Infection

Interventions: Device: Negative Pressure Pressure Wound Therapy
Procedure: Standard Wound Care

First Posted Date: 2019-05-02

Last Posted Date: 2021-02-10

Lead Sponsor: Henry Ford Health System

Registration Number: NCT03935659

Locations: 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States

Phase I Study MR-guided SBRT to PCa

Not Applicable

Withdrawn

Conditions: Low or Intermediate Risk Prostate Cancer

Interventions: Radiation: MR guided Linear Accelerator

First Posted Date: 2019-05-02

Last Posted Date: 2022-02-25

Lead Sponsor: Henry Ford Health System

Registration Number: NCT03935308

Locations: 🇺🇸
Henry Ford Health System, Detroit, Michigan, United States

The Efficacy and Molecular Mechanism of Botulinum Toxin in the Reduction of Breast Reduction Mammoplasty Scar Formation

Phase 2

Conditions: Mammary Disorder
Scar
Hypertrophic Scar

Interventions: Drug: Botulinum Toxins
Other: Normal saline

First Posted Date: 2019-03-25

Last Posted Date: 2024-04-04

Lead Sponsor: Henry Ford Health System

Target Recruit Count: 22

Registration Number: NCT03887377

Locations: 🇺🇸
Henry Ford Health System, Detroit, Michigan, United States

Dexamethasone Administered Via the Epidural Catheter as an Adjunct in Patients Undergoing Cesarean Delivery

Phase 4

Withdrawn

Conditions: Post Operative Pain

Interventions: Drug: Dexamethasone

First Posted Date: 2019-03-15

Last Posted Date: 2023-09-26

Lead Sponsor: Henry Ford Health System

Registration Number: NCT03877549

Locations: 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States

Fractional Laser Assisted Delivery of Sculptra® for the Treatment of Striae

Early Phase 1

Completed

Conditions: Striae Distensae

Interventions: Device: Fractional laser treatment
Drug: Poly-L Lactic Acid

First Posted Date: 2019-02-28

Last Posted Date: 2021-08-26

Lead Sponsor: Henry Ford Health System

Target Recruit Count: 10

Registration Number: NCT03858543

Locations: 🇺🇸
Henry Ford Health System, Detroit, Michigan, United States

Subscapularis Strength After Total Shoulder Arthroplasty

Not Applicable

Completed

Conditions: Shoulder Osteoarthritis

Interventions: Procedure: Subscapularis Rehabilitation
Procedure: Standard Rehabilitation

First Posted Date: 2019-02-26

Last Posted Date: 2022-11-04

Lead Sponsor: Henry Ford Health System

Target Recruit Count: 66

Registration Number: NCT03854357

Locations: 🇺🇸
Henry Ford Health Systems, Detroit, Michigan, United States

Immuno-regulatory Profiling of T Cells in GVHD Treated With Extracorporeal Photopheresis

Completed

Conditions: GVHD

Interventions: Other: blood samples

First Posted Date: 2019-02-22

Last Posted Date: 2023-10-26

Lead Sponsor: Henry Ford Health System

Target Recruit Count: 6

Registration Number: NCT03851601

Locations: 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States

Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant

Phase 2

Active, not recruiting

Conditions: Prophylaxis
Stem Cell Transplant Complications

Interventions: Drug: Levofloxacin
Drug: Ciprofloxacin

First Posted Date: 2019-02-21

Last Posted Date: 2024-04-23

Lead Sponsor: Henry Ford Health System

Target Recruit Count: 308

Registration Number: NCT03850379

Locations: 🇺🇸
Henry Ford, Detroit, Michigan, United States

HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib

Phase 2

Recruiting

Conditions: Hematological Malignancy

Interventions: Drug: Bortezomib

First Posted Date: 2019-02-21

Last Posted Date: 2024-01-05

Lead Sponsor: Henry Ford Health System

Target Recruit Count: 15

Registration Number: NCT03850366

Locations: 🇺🇸
Henry Ford hospital, Detroit, Michigan, United States

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Phase 2

Recruiting

Conditions: Myeloid Malignancy

Interventions: Drug: azacitidine

First Posted Date: 2019-02-21

Last Posted Date: 2024-01-05

Lead Sponsor: Henry Ford Health System

Target Recruit Count: 43

Registration Number: NCT03850418

Locations: 🇺🇸
Henry ford hospital, Detroit, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy